Status:
UNKNOWN
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
AL Amyloidosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined ...
Eligibility Criteria
Inclusion
- 18 years and older
- newly diagnosed or refractory/relapsed AL amyloidosis
- treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy
Exclusion
- co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia
Key Trial Info
Start Date :
March 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05277493
Start Date
March 30 2022
End Date
September 1 2025
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China